PK/PD of High Dose Pip/Tazo in Obese Patients

Overview

Worldwide rates of obesity have doubled in the last 30 years, and obesity has been associated as a risk factor for hospital-acquired infections and increased occurrence of death in critically-ill patients. Piperacillin/tazobactam is a commonly prescribed antibiotic for critically ill patients with an infection, however, limited information exists for dosing this drug in obese patients. In these limited reports, standard doses of piperacillin/tazobactam given to the small number of obese patients resulted in lower blood concentrations, which could lead to inadequate killing of bacteria. The purpose of this study is to compare blood concentrations from standard piperacillin/tazobactam dosing compared to higher dosing regimens in obese patients. This study will also include information on the safety and tolerability of the higher dose regimens. The study investigators believe that the higher dosing regimen will produce adequate blood levels in obese patients and will not add any more risk of harm to obese patients receiving this higher dose.

Full Title of Study: “Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin/Tazobactam in Obese Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 23, 2016

Interventions

  • Drug: Piperacillin/Tazobactam Standard Dose to High Dose
    • Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.

Arms, Groups and Cohorts

  • Experimental: Standard Dose to High Dose Piperacillin/Tazobactam
    • Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.

Clinical Trial Outcome Measures

Primary Measures

  • Serum Maximum Concentrations for Piperacillin
    • Time Frame: 0, 1, 3, and 6 hours post-dose
    • Pharmacokinetic parameters for piperacillin of maximum serum concentration (Cmax) will be measured in both standard dosing and high dosing.
  • Serum Minimum Concentrations of Piperacillin
    • Time Frame: 0, 1, 3, and 6 hours post-dose
    • Minimum serum concentrations (Cmin) of piperacillin will be measured in both standard and high doses

Secondary Measures

  • Half-life of Piperacillin
    • Time Frame: 0, 1, 3, and 6 hours post-dose
    • Half-life (t1/2) of piperacillin will be calculated from serum concentrations in both standard and high doses
  • Volume of Distribution of Piperacillin
    • Time Frame: 0, 1, 3, and 6 hours post-dose
    • Volume of distribution (Vd) of piperacillin will be calculated from serum concentrations in both standard and high doses

Participating in This Clinical Trial

Inclusion Criteria

  • BMI greater than or equal to 30 kg/m2 – Weight at least 105 kg – Age 18-89 years of age – Prescribed piperacillin/tazobactam at standard doses for suspected or confirmed infection(s) – English or Spanish speaking – Central line access Exclusion Criteria:

  • Do not meet specified inclusion criteria – Hepatic impairment classified by Child-Pugh Class B or greater – Documented pre-existing seizure disorder – Documented pre-existing hematologic disorder – Pregnancy – Documented allergy or contraindication to beta-lactams or tazobactam

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 89 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Loma Linda University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Steven Forland, Clinical Pharmacy Specialist – Infectious Diseases – Loma Linda University
  • Overall Official(s)
    • Steven C Forland, PharmD, Principal Investigator, Loma Linda University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.